In industrial settings, people can be exposed to titanium dioxide through inhalation. Inhalation exposure to titanium dioxide is exceedingly rare for most people.
On November 23, 2022, the General Court of the European Union reversed the conclusion that titanium dioxide was carcinogenic and released a statement (1,2):
“First, the Commission made a manifest error in its assessment of the reliability and acceptability of the study on which the classification was based and, second, it infringed the criterion according to which that classification can relate only to a substance that has the intrinsic property to cause cancer.”
As part of our mission at CRIS we base our safety assessments on the currently available scientific evidence and consider many variables (e.g., study quality, journal of publication, etc.), even if it goes against previous conclusions. Evidence-informed decisions making is critical to ensure that the laws and regulations put into place are for the benefit of the population.
The EU General Court maintains that the scientific evidence presented wasn’t the complete picture for the ingredient, “in the present case, the requirement to base the classification of a carcinogenic substance on reliable and acceptable studies was not satisfied.”
Titanium dioxide is one of the most widely used white pigments, often used to add whiteness and brightness to products. It is used in the production of paints, coatings, plastics and other products to provide a white color or opacity.
Recently, Yanagisawa et al. reported that the transdermal exposure (mimicking skin-barrier dysfunction or defect) of NC/Nga mice to TiO2 NPs (15, 50, or 100 nm), in combination with allergen, aggravated atopic dermatitis-like lesions through a T-helper type 2 (Th2) dominant immune response. The study also indicated that TiO2 NPs can play a role in the initiation and/or progression of skin diseases, since histamine was released, even in the absence of allergen.
